
WE CLAIM:

1. A compound of formula I:



I

wherein

X is N or CH;

R^1 is H, CD_3, C_{1-3} alkyl or C_{3-6} cycloalkyl;

R^2 is C_{1-6} alkyl, C_{1-6} alkoxy, $-(CH_2)_r$-3-14 membered carbocycle substituted with 0-1 R^{2a}, $-NR^aC_{1-6}$ alkyl substituted with 0-2 R^{2a}, $-NR^a$-aryl substituted with 0-2 R^{2a}, $-NR^a$-heterocycle substituted with 0-2 R^{2a}, NR^aCO-C_{1-6} alkyl, NR^a-C_{3-6} cycloalkyl substituted with 0-2 R^{2a} or a 5-8 membered heterocycle substituted with 0-3 R^{2a};

R^{2a} is independently at each occurrence, H, CN, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} aryl or a 5-8 membered heterocycle

R^3 is C_{1-3} alkyl, C_{1-3} alkoxy, $-NHS(O)_pR^a$ or $-S(O)_pR^a$;R^4 is absent or a 5-7 membered heterocycle substituted with 0-3 R^5;

R^5 is H, halogen, C_{1-3} alkyl, C_{1-3} alkyl C_{1-3} alkoxy, --$(CH_2)_r$ 5-8 membered heterocycle substituted with 0-2 R^{5a} or -CO-3-8 membered heterocycle;

R^{5a} is SO_2- C_{1-6} alkyl or COO- C_{1-6} alkyl;


R^a is C_{1-3} alkyl or C_{3-6} cycloalkyl;

p is 1 or 2;

r is 0, 1, 2, 3, 4 or 5;

or a stereoisomer or pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 of the formula



I

wherein

X is N or CH;

R^1 is H or CD_3;

R^2 is C_{1-6} alkyl, C_{1-6} alkoxy, -$(CH_2)_r$-3-14 membered carbocycle substituted with 0-1 R^{2a}, -NR^aC_{1-6} alkyl substituted with 0-2 R^{2a}, -NR^a-aryl substituted with 0-2 R^{2a}, -NR^a-heterocycle substituted with 0-2 R^{2a}, NR^aCO-C_{1-6} alkyl, NR^a-C_{3-6} cycloalkyl substituted with 0-2 R^{2a} or a 5-8 membered heterocycle substituted with 0-3 R^{2a};

R^{2a} is independently at each occurrence, H, CN, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} aryl or a 5-8 membered heterocycle

R^3 is C_{1-3} alkyl, C_{1-3} alkoxy, -$NHS(O)_pR^a$ or -$S(O)_pR^a$;R^4 is absent or a 5-7 membered heterocycle substituted with 0-3 R^5;

R^5 is H, halogen, C_{1-3} alkyl, C_{1-3} alkyl C_{1-3} alkoxy, --$(CH_2)_r$ 5-8 membered heterocycle substituted with 0-2 R^{5a} or -CO-3-8 membered heterocycle;

R^{5a} is SO_2- C_{1-6} alkyl or COO- C_{1-6} alkyl;


R^a is C_{1-3} alkyl or C_{3-6} cycloalkyl;

p is 1 or 2;

r is 0, 1, 2, 3, 4 or 5;

or a stereoisomer or pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 of the formula



I

wherein

X is N or CH;

R^1 is H or CD_3;

R^2 is C_{1-6} alkyl, C_{1-6} alkoxy, -$(CH_2)_r$-3-14 membered carbocycle substituted with 0-1 R^{2a}, -NR^aC_{1-6} alkyl substituted with 0-2 R^{2a}, -NR^a-aryl substituted with 0-2 R^{2a}, -NR^a-heterocycle substituted with 0-2 R^{2a}, NR^aCO-C_{1-6} alkyl, NR^a-C_{3-6} cycloalkyl substituted with 0-2 R^{2a} or a 5-8 membered heterocycle substituted with 0-3 R^{2a};

R^{2a} is independently at each occurrence, H, CN, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} aryl or a 5-8 membered heterocycle

R^3 is C_{1-3} alkyl, C_{1-3} alkoxy, -$NHS(O)_pR^a$ or -$S(O)_pR^a$;R^4 is absent or a 5-7 membered heterocycle substituted with 0-3 R^5;

R^5 is H, halogen, C_{1-3} alkyl, C_{1-3} alkyl C_{1-3} alkoxy, --$(CH_2)_r$ 5-8 membered heterocycle substituted with 0-2 R^{5a} or -CO-3-8 membered heterocycle;

R^{5a} is SO_2- C_{1-6} alkyl or COO- C_{1-6} alkyl;


R^a is C_{1-3} alkyl or C_{3-6} cycloalkyl;

p is 2;

r is 0, 1, 2, 3, 4 or 5;

or a stereoisomer or pharmaceutically acceptable salt thereof.

4. The compound according to claim 3 of the formula



wherein

X is N or CH;

R^2 is C_{1-6} alkyl, C_{1-6} alkoxy, -$(CH_2)_r$-3-14 membered carbocycle substituted with 0-1 R^{2a}, -NR^aC_{1-6} alkyl substituted with 0-2 R^{2a}, -NR^a-aryl substituted with 0-2 R^{2a}, -NR^a-heterocycle substituted with 0-2 R^{2a}, NR^aCO-C_{1-6} alkyl, NR^a-C_{3-6} cycloalkyl substituted with 0-2 R^{2a} or a 5-8 membered heterocycle substituted with 0-3 R^{2a};

R^{2a} is independently at each occurrence, H, CN, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} aryl or a 5-8 membered heterocycle

R^3 is C_{1-3} alkyl, C_{1-3} alkoxy, -$NHS(O)_pR^a$ or -$S(O)_pR^a$;R^4 is absent or a 5-7 membered heterocycle substituted with 0-3 R^5;

R^5 is H, halogen, C_{1-3} alkyl, C_{1-3} alkyl C_{1-3} alkoxy, --$(CH_2)_r$ 5-8 membered heterocycle substituted with 0-2 R^{5a} or -CO-3-8 membered heterocycle;

R^{5a} is SO_2- C_{1-6} alkyl or COO- C_{1-6} alkyl;


R^a is C_{1-3} alkyl or C_{3-6} cycloalkyl;

p is 2;

r is 0, 1, 2, 3, 4 or 5;

or a stereoisomer or pharmaceutically acceptable salt thereof.

5. The compound according to claim 4 of the formula



wherein

X is N or CH;

R^2 is C_{1-6} alkyl, C_{1-6} alkoxy, -$(CH_2)_r$-3-14 membered carbocycle substituted with 0-1 R^{2a}, -NR^aC_{1-6} alkyl substituted with 0-2 R^{2a}, -NR^a-aryl substituted with 0-2 R^{2a}, -NR^a-heterocycle substituted with 0-2 R^{2a}, NR^aCO-C_{1-6} alkyl, NR^a-C_{3-6} cycloalkyl substituted with 0-2 R^{2a} or a 5-8 membered heterocycle substituted with 0-3 R^{2a};

R^{2a} is independently at each occurrence, H, CN, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} aryl or a 5-8 membered heterocycle

R^3 is C_{1-3} alkyl, C_{1-3} alkoxy, -$NHS(O)_pR^a$ or -$S(O)_pR^a$;R^4 is absent or a 5-7 membered heterocycle substituted with 0-3 R^5;

R^5 is H, halogen, C_{1-3} alkyl, C_{1-3} alkyl C_{1-3} alkoxy, --$(CH_2)_r$ 5-8 membered heterocycle substituted with 0-2 R^{5a} or -CO-3-8 membered heterocycle;

R^{5a} is SO_2- C_{1-6} alkyl or COO- C_{1-6} alkyl;


R^a is C_{1-3} alkyl or C_{3-6} cycloalkyl;

p is 2;

r is 0, 1 or 2;

or a stereoisomer or pharmaceutically acceptable salt thereof.

6. The compound according to claim 5 of the formula



wherein

X is N or CH;

R^2 is C_{1-6} alkyl, C_{1-6} alkoxy, -$(CH_2)_r$-3-14 membered carbocycle substituted with 0-1 R^{2a}, -NR^aC_{1-6} alkyl substituted with 0-2 R^{2a}, -NR^a-aryl substituted with 0-2 R^{2a}, -NR^a-heterocycle substituted with 0-2 R^{2a}, NR^aCO-C_{1-6} alkyl, NR^a-C_{3-6} cycloalkyl substituted with 0-2 R^{2a} or a 5-8 membered heterocycle substituted with 0-3 R^{2a};

R^{2a} is independently at each occurrence, H, CN, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} aryl or a 5-8 membered heterocycle

R^4 is absent or a 5-7 membered heterocycle substituted with 0-3 R^5;

R^5 is H, halogen, C_{1-3} alkyl, C_{1-3} alkyl C_{1-3} alkoxy, --$(CH_2)_r$ 5-8 membered heterocycle substituted with 0-2 R^{5a} or -CO-3-8 membered heterocycle;

R^{5a} is SO_2- C_{1-6} alkyl or COO- C_{1-6} alkyl;


R^a is C_{1-3} alkyl or C_{3-6} cycloalkyl;

p is 2;

r is 0, 1 or 2;

or a stereoisomer or pharmaceutically acceptable salt thereof.

7. The compound according to claim 6 of the formula



wherein

X is N or CH;

R^2 is C_{1-6} alkyl, C_{1-6} alkoxy, -$(CH_2)_r$-3-14 membered carbocycle substituted with 0-1 R^{2a}, -NR^aC_{1-6} alkyl substituted with 0-2 R^{2a}, -NR^a-aryl substituted with 0-2 R^{2a}, -NR^a-heterocycle substituted with 0-2 R^{2a}, NR^aCO-C_{1-6} alkyl, NR^a-C_{3-6} cycloalkyl substituted with 0-2 R^{2a} or a 5-8 membered heterocycle substituted with 0-3 R^{2a};

R^{2a} is independently at each occurrence, H, CN, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} aryl or a 5-8 membered heterocycle

R^4 is absent or a triazole, thiazole, tetrazole or oxadiazole group each of which is substituted with 0-3 R^5;

R^5 is H, halogen, C_{1-3} alkyl, C_{1-3} alkyl C_{1-3} alkoxy, --$(CH_2)_r$ 5-8 membered heterocycle substituted with 0-2 R^{5a} or -CO-3-8 membered heterocycle;

R^{5a} is SO_2- C_{1-6} alkyl or COO- C_{1-6} alkyl;


R^a is C_{1-3} alkyl or C_{3-6} cycloalkyl;

p is 2;

r is 0, 1 or 2;

or a stereoisomer or pharmaceutically acceptable salt thereof.

8. The compound according to claim 1 of the formula



wherein

R^1 is H, CD_3, C_{1-3} alkyl or C_{3-6} cycloalkyl;

R^2 is C_{1-6} alkyl, C_{1-6} alkoxy, -$(CH_2)_r$-3-14 membered carbocycle substituted with 0-1 R^{2a}, -NR^aC_{1-6} alkyl substituted with 0-2 R^{2a}, -NR^a-aryl substituted with 0-2 R^{2a}, -NR^a-heterocycle substituted with 0-2 R^{2a}, NR^aCO-C_{1-6} alkyl, NR^a-C_{3-6} cycloalkyl substituted with 0-2 R^{2a} or a 5-8 membered heterocycle substituted with 0-3 R^{2a};

R^{2a} is independently at each occurrence, H, CN, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} aryl or a 5-8 membered heterocycle

R^3 is C_{1-3} alkyl, C_{1-3} alkoxy, -$NHS(O)_pR^a$ or -$S(O)_pR^a$;R^4 is absent or a 5-7 membered heterocycle substituted with 0-3 R^5;

R^5 is H, halogen, C_{1-3} alkyl, C_{1-3} alkyl C_{1-3} alkoxy, --$(CH_2)_r$ 5-8 membered heterocycle substituted with 0-2 R^{5a} or -CO-3-8 membered heterocycle;

R^{5a} is SO_2- C_{1-6} alkyl or COO- C_{1-6} alkyl;


R^a is C_{1-3} alkyl or C_{3-6} cycloalkyl;

p is 1 or 2;

r is 0, 1, 2, 3, 4 or 5;

or a stereoisomer or pharmaceutically acceptable salt thereof.

9. The compound according to claim 1 of the formula



wherein

R^1 is H, CD_3, C_{1-3} alkyl or C_{3-6} cycloalkyl;

R^2 is C_{1-6} alkyl, C_{1-6} alkoxy, -$(CH_2)_r$-3-14 membered carbocycle substituted with 0-1 R^{2a}, -NR^aC_{1-6} alkyl substituted with 0-2 R^{2a}, -NR^a-aryl substituted with 0-2 R^{2a}, -NR^a-

heterocycle substituted with 0-2 R^{2a}, NR^aCO-C_{1-6} alkyl, NR^a-C_{3-6} cycloalkyl substituted with 0-2 R^{2a} or a 5-8 membered heterocycle substituted with 0-3 R^{2a};

R^{2a} is independently at each occurrence, H, CN, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} aryl or a 5-8 membered heterocycle

R^3 is C_{1-3} alkyl, C_{1-3} alkoxy, $-NHS(O)_pR^a$ or $-S(O)_pR^a$;R^4 is absent or a 5-7 membered heterocycle substituted with 0-3 R^5;

R^5 is H, halogen, C_{1-3} alkyl, C_{1-3} alkyl C_{1-3} alkoxy, $--(CH_2)_r$ 5-8 membered heterocycle substituted with 0-2 R^{5a} or -CO-3-8 membered heterocycle;

R^{5a} is SO_2- C_{1-6} alkyl or COO- C_{1-6} alkyl;

R^a is C_{1-3} alkyl or C_{3-6} cycloalkyl;

p is 1 or 2;

r is 0, 1, 2, 3, 4 or 5;

or a stereoisomer or pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising one or more compounds according to any one of claims 1-9 and a pharmaceutically acceptable carrier or diluent.

11. Use of a compound according to any one of claims 1-9 in the manufacture of a medicament for treating a disease, wherein a therapeutically-effective amount of the compound is to be administered to a patient in need of such treatment, wherein the disease is an inflammatory or autoimmune disease.

12. The use of claim 11 wherein the inflammatory or autoimmune disease is multiple sclerosis, rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis, psoriatic arthritis, Crohn’s Disease, Sjögren’s syndrome or scleroderma.

13. A compound according to any one of claims 1-9 for use in therapy.